Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

What top Australian equity managers bought and sold last quarter

Lewis Jackson  |  16 Jul 2021Text size  Decrease  Increase  |  
Email to Friend

Just over 92 million shares traded hands on the ASX in the June quarter, about a million shares a day. We’ve looked through the churn to see what top-rated Morningstar fund managers bought and sold.

Australian fund managers typically report their largest holdings on a monthly or quarterly basis. We’ve compared those reports to see what’s changed in their portfolios between April and June.

We’ve included Australian equity managers with a Gold or Silver analyst rating, meaning they score highly on five key metrics: people, process, performance, parent and price. Funds that earn a Gold rating are those that analysts think are most likely to outperform over a full market cycle.

We’ve included those names covered by Morningstar and ranked them to how undervalued they are.

Buyout targets among the list

Silver-rated small-cap Australian equity fund Investors Mutual Future Leaders picked up Australian Pharmaceutical Industries (API) while sister fund Equity Income bought Spark Infrastructure (SKI) in April.

Both have been targeted by acquisitions this month.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

Morningstar analysts are not fully sold on the offers. Analyst Shane Ponraj called the $687 offer for API from Wesfarmers “opportunistic”, saying it undervalues the company. Analyst Adrian Atkins called the rejected $5 billion plus bid for SKI from private equity giant KKR and the Ontario Teacher’s Pension Plan “mediocre”.

The moves follow Sydney Airport turning down a $22 billion offer as buyers circle infrastructure assets.

SKI is up 14 per cent and API 21 per cent since the announcements.

Turnover among the WAAAXs

Silver-rated large Australian equity fund Hyperion Australian Growth Companies has bumped up its stake in Afterpay (APT) even as it said goodbye to part of its holdings of Xero (XRO) and WiseTech (WTC).

Big changes in some overvalued names

Hyperion Australian Growth Companies made some big changes--greater than 5 per cent of the whole portfolio--for a handful of names Morningstar considers overvalued.

It bought a stake equivalent to 11.55 per cent of the portfolio in sleeping disorder treatment provider ResMed (RMD), which last closed at $33.40, a 76 per cent premium on the $19 Morningstar fair value.

It has also sold big stakes in Cochlear (COH) and Dominos Pizza Enterprise (DMP), both trading in the one-star range, meaning a significant premium to fair value.

The one fairly valued name picked up by the fund was CSL Ltd (CSL), which had its fair value increased 13 per cent yesterday after an upgrade to its potential for gross margin expansion. The Australian biotech giant closed Friday at $277.72, just above its new fair value estimate of $275

is a reporter and data journalist with Morningstar. Tweet him @lewjackk or get in touch via email

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend